HanAll Biopharma Posts 920 Million Won Operating Loss Last Year, Swings to Deficit

HanAll Biopharma announced on the 21st that, on a consolidated basis, it posted an operating loss of 920 million won last year, turning to a deficit according to provisional figures.

Revenue reached 155.2 billion won, up 11.7% from the previous year. The net loss widened to 5.6 billion won. The operating loss for the fourth quarter was 2 billion won, turning to a deficit compared to an operating profit of 2.7 billion won in the same period of the previous year. For the quarter, revenue and net loss were 37.5 billion won and 6.2 billion won, respectively.

This content was produced with the assistance of AI translation services.